ung cancer Early Molecular Assessment trial

• Conditions: non-small cell lung cancer; 10038666

• Registration Number: NL-OMON47319
• Lead Sponsor: Antoni van Leeuwenhoek Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 1297

Inclusion Criteria

- Suspicion of lung carcinoma or established NSCLC but awaiting start of definitive treatment
- Written informed consent to undergo diagnostic procedure and molecular analysis of the disease.

Exclusion Criteria

- Not motivated to receive any treatment at any point in time. Patients who consider undergoing treatment in the future are eligible.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The percentage of patients with EGFR mutation or ALK translocation using the<br /><br>combined tumour tissue and liquid biopsy analysis.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary endpoints include the test performance of both techniques in<br /><br>different stage of disease, the percentage of patients with a predefined<br /><br>actionable genetic alteration, the costs, and the influence of the liquid<br /><br>biopsies on the diagnostic yield of tissue molecular and pathological analysis.</p><br>